- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of December 2
The Center for Biosimilars® recaps the top stories for the week of December 2, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 2, 2019.
Number 5: Writing in a perspective article in The New England Journal of Medicine, a noted critic of high pharmaceutical prices proposed targets for drug price negotiation.
Number 4: A recent study reports that pricing decisions for multiple sclerosis drugs are not the result of needing to recoup specific research and development costs.
Number 3: The FDA released draft guidance for industry on clinical immunogenicity considerations for biosimilar insulins and interchangeable insulins.
Number 2: The European Commission has released a new report that highlights the role that biosimilars and generics will have in the well-being of European healthcare systems in the years ahead.
Number 1: Mylan and Biocon announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States.
Finally, last week, our e-newsletter asked which group you think has the greatest responsibility to educate patients about biosimilars and biologics.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
